Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares conducted on March 5, 2026. The filing was submitted on March 6, 2026. The transaction was executed by BNP Paribas SA acting as a broker under a non-discretionary agreement announced on February 17, 2026, as part of GSK's existing share buyback program.
Key Financial Metrics
The filing details the specific parameters of the share repurchase transaction:
- Shares Purchased: 650,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,072.00 GBp; highest price paid was 2,135.00 GBp.
- Average Price: Volume-weighted average price paid was 2,102.05 GBp.
- Trading Venues: Purchases were made across BATE, CHIX, and XLON (London Stock Exchange).
- Treasury Holdings: Following this purchase, GSK holds 246,357,094 ordinary shares in treasury.
- Shares in Issue: 4,069,805,394 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 6.05% of total voting rights.
Material Changes
Since the commencement of the current buyback agreement on February 17, 2026, GSK has purchased a total of 6,466,000 ordinary shares. The filing does not provide comparative financial data (revenue, profit, or cash flow) for the period, as it is a transaction-specific disclosure rather than a periodic financial report.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the company's Annual Report on Form 20-F for 2024 and the 2025 Annual Report. No new guidance or management commentary regarding operational outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of shares purchased under the current buyback program (6,466,000 since Feb 17, 2026).
- Confirm the updated treasury share count (246,357,094) and its impact on voting rights (6.05%).
- Review the volume-weighted average price (2,102.05 GBp) against current market valuations.
- Check the remaining capacity or authorization limits of the existing buyback program announced on February 17, 2026.
- Consult the referenced 2024 and 2025 Annual Reports for detailed risk factors affecting the company.